Journal
MARINE DRUGS
Volume 20, Issue 2, Pages -Publisher
MDPI
DOI: 10.3390/md20020098
Keywords
tuberculosis; dormant; antibiotics; aaptamine; structure-activity relationship; probe molecule
Categories
Ask authors/readers for more resources
The current treatment for tuberculosis is long and complex due to the ability of Mycobacterium tuberculosis to enter a dormant state. Identifying new compounds with different chemical structures is essential for improving treatment outcomes. This study investigates the structure-activity relationship of a potential anti-tuberculosis compound and successfully develops a probe molecule for detecting its target protein.
The current tuberculosis treatment regimen is long and complex, and its failure leads to relapse and emergence of drug resistance. One of the major reasons underlying the extended chemotherapeutic regimen is the ability of Mycobacterium tuberculosis to attain a dormant state. Therefore, the identification of new lead compounds with chemical structures different from those of conventional anti-tuberculosis drugs is essential. The compound 3-(phenethylamino)demethyl(oxy)aaptamine (PDOA, 1), isolated from marine sponge of Aaptos sp., is known as an anti-dormant mycobacterial substance, and has been reported to be effective against the drug resistant strains of M. tuberculosis. However, its target protein still remains unclear. This study aims to clarify the structure-activity relationship of 1 using 15 synthetic analogues, in order to prepare a probe molecule for detecting the target protein of 1. We succeeded in creating the compound 15 with a photoaffinity group that retained antimicrobial activity, which proved to be a suitable probe molecule for identifying the target protein of 1.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available